166 related articles for article (PubMed ID: 20594221)
1. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
[TBL] [Abstract][Full Text] [Related]
2. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
3. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
4. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
[TBL] [Abstract][Full Text] [Related]
7. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
Murphy MD; Rosen HR; Marousek GI; Chou S
Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
[TBL] [Abstract][Full Text] [Related]
9. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
[TBL] [Abstract][Full Text] [Related]
10. The evolving treatment of chronic hepatitis C: where we stand a decade out.
Saadeh S; Davis GL
Cleve Clin J Med; 2004 May; 71 Suppl 3():S3-7. PubMed ID: 15468610
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
Fattovich G; Zagni I; Fornaciari G; Minola E; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Montanari R; Paternoster C; Distasi M; Castagnetti E; Tositti G; Rizzo C; Suppressa S; Pantalena M; Lomonaco L; Scattolini C; Tagger A
J Viral Hepat; 2003 Mar; 10(2):111-7. PubMed ID: 12614467
[TBL] [Abstract][Full Text] [Related]
12. Antiviral action of ribavirin in chronic hepatitis C.
Pawlotsky JM; Dahari H; Neumann AU; Hezode C; Germanidis G; Lonjon I; Castera L; Dhumeaux D
Gastroenterology; 2004 Mar; 126(3):703-14. PubMed ID: 14988824
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.
Cornberg M; Wedemeyer H; Manns MP
Curr Gastroenterol Rep; 2002 Feb; 4(1):23-30. PubMed ID: 11825538
[TBL] [Abstract][Full Text] [Related]
14. ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.
Cappiello G; Abbate I; Lo Iacono O; Longo R; Solmone M; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxi A; Ippolito G; Capobianchi MR
Antivir Ther; 2003 Apr; 8(2):105-10. PubMed ID: 12741622
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis c patients infected by genotype 1b.
Scotto G; Campanozzi F; D'Adduzio A; Grimaldi M; Fazio V
BioDrugs; 2003; 17(4):281-6. PubMed ID: 12899645
[TBL] [Abstract][Full Text] [Related]
16. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.
Sarrazin C; Berg T; Lee JH; Teuber G; Dietrich CF; Roth WK; Zeuzem S
J Hepatol; 1999 Jun; 30(6):1004-13. PubMed ID: 10406177
[TBL] [Abstract][Full Text] [Related]
17. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin.
Nakajima H; Shimomura H; Iwasaki Y; Ikeda F; Umeoka F; Chengyu P; Taniguchi H; Ohnishi Y; Takagi SJ; Fujioka S; Shiratori Y
Acta Med Okayama; 2003 Oct; 57(5):217-25. PubMed ID: 14679399
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
[TBL] [Abstract][Full Text] [Related]
19. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin.
Lavezzo B; Franchello A; Smedile A; David E; Barbui A; Torrani M; Ottobrelli A; Zamboni F; Fadda M; Bobbio A; Salizzoni M; Rizzetto M
J Hepatol; 2002 Aug; 37(2):247-52. PubMed ID: 12127430
[TBL] [Abstract][Full Text] [Related]
20. NS5A mutations predict biochemical but not virological response to interferon-alpha treatment of sporadic hepatitis C virus infection in European patients.
Stratidaki I; Skoulika E; Kelefiotis D; Matrella E; Alexandrakis G; Economou A; Kouroumalis E
J Viral Hepat; 2001 Jul; 8(4):243-8. PubMed ID: 11454174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
